Discounted Cash Flow Rating

Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Neutral

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Kronos Worldwide, Inc. (KRO)

Industrial Inorganic Chemicals

https://www.kronostio2.com

Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in a variety of products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second- largest product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.

5430 LBJ FREEWAY, SUITE 1700
DALLAS, TX

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/05/2003

Market Cap

1,298,756,440

Shares Outstanding

115,030,000

Weighted SO

115,027,016

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

ODC --.--%

KWR --.--%

ECVT --.--%

MTX --.--%

ESI --.--%

PRM --.--%

SXT --.--%

TSE --.--%

WTTR --.--%

Beta

1.1640

Last Div

0.2000

Range

6.16-14.5

Chg

-0.2100

Avg Vol

272353

Mkt Cap

1298756440

Exch

NYSE

Country

US

Phone

972 233 1700

DCF Diff

6.8989

DCF

4.6012

Div Yield

0.0673

P/S

0.7312

EV Multiple

15.9283

P/FV

1.6762

Div Yield %

6.7316

P/E

683.3421

PEG

-4.6241

Payout

46.0000

Current Ratio

3.6148

Quick Ratio

1.9773

Cash Ratio

0.4962

DSO

76.1521

DIO

108.6304

Op Cycle

184.7825

DPO

31.5543

CCC

153.2282

Gross Margin

0.1541

Op Margin

0.0226

Pretax Margin

0.0006

Net Margin

0.0011

Eff Tax Rate

-0.7273

ROA

0.0011

ROE

0.0024

ROCE

0.0291

NI/EBT

1.7273

EBT/EBIT

0.0274

EBIT/Rev

0.0226

Debt Ratio

0.2580

D/E

0.5518

LT Debt/Cap

0.3536

Total Debt/Cap

0.3556

Int Coverage

5.0250

CF/Debt

0.1781

Equity Multi

2.1390

Rec Turnover

4.7930

Pay Turnover

11.5674

Inv Turnover

3.3600

FA Turnover

3.8085

Asset Turnover

1.0721

OCF/Share

0.6617

FCF/Share

0.4739

Cash/Share

1.1783

OCF/Sales

0.0428

FCF/OCF

0.7162

CF Coverage

0.1781

ST Coverage

20.5676

CapEx Coverage

3.5231

Div&CapEx Cov

0.6982

P/BV

1.6762

P/B

1.6762

P/S

0.7312

P/E

683.3421

P/FCF

23.8304

P/OCF

17.0611

P/CF

17.0611

PEG

-4.6241

P/S

0.7312

EV Multiple

15.9283

P/FV

1.6762

DPS

0.7600

Latest Headlines (EST)

GlobeNewswire Inc. May 18, 22:41 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders GlobeNewswire Inc. May 17, 17:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – PRA, KRON, AXL, SWTX Benzinga May 16, 22:30 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - PRA, KRON, AXL, SWTX GlobeNewswire Inc. May 15, 22:52 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders GlobeNewswire Inc. May 10, 16:28 Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der Fibr GlobeNewswire Inc. May 10, 16:28 Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH), mon GlobeNewswire Inc. May 10, 14:28 Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt GlobeNewswire Inc. May 10, 14:28 Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine GlobeNewswire Inc. May 10, 14:00 Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025 GlobeNewswire Inc. May 03, 20:37 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders GlobeNewswire Inc. Apr 07, 21:59 INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm GlobeNewswire Inc. Feb 28, 22:00 Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences The Motley Fool Feb 02, 23:21 This Stock Just Doubled in 1 Day -- Is It Still a Buy? GlobeNewswire Inc. Jan 29, 02:30 Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Investing.com Jul 19, 02:21 Akero Therapeutics CFO sells over $976k in company stock - Investing.com GlobeNewswire Inc. Jan 23, 06:21 KRONOS WORLDWIDE ANNOUNCES EXCHANGE OFFER AND CONSENT SOLICITATION GlobeNewswire Inc. Jan 03, 21:29 Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Jan 03, 21:29 Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Jan 03, 21:29 Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock GlobeNewswire Inc. Jan 03, 21:29 Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.19 06/10/2024 05/15/2024 06/10/2024 06/20/2024
0.19 03/04/2024 02/21/2024 03/05/2024 03/14/2024
0.19 11/30/2023 10/25/2023 12/01/2023 12/14/2023
0.19 08/31/2023 08/02/2023 09/01/2023 09/14/2023
0.19 06/02/2023 05/17/2023 06/05/2023 06/15/2023
0.19 03/06/2023 02/22/2023 03/07/2023 03/16/2023
0.19 11/30/2022 10/26/2022 12/01/2022 12/15/2022
0.19 08/31/2022 08/03/2022 09/01/2022 09/15/2022
0.19 06/03/2022 05/18/2022 06/06/2022 06/16/2022
0.19 03/07/2022 02/23/2022 03/08/2022 03/17/2022
0.18 12/01/2021 10/27/2021 12/02/2021 12/16/2021
0.18 09/01/2021 08/04/2021 09/02/2021 09/16/2021
0.18 06/04/2021 05/19/2021 06/07/2021 06/17/2021
0.18 03/08/2021 02/24/2021 03/09/2021 03/18/2021
0.18 11/30/2020 10/28/2020 12/01/2020 12/10/2020
0.18 08/31/2020 08/05/2020 09/01/2020 09/10/2020
0.18 06/08/2020 05/20/2020 06/09/2020 06/18/2020
0.18 03/02/2020 02/19/2020 03/03/2020 03/12/2020
0.18 12/02/2019 10/23/2019 12/03/2019 12/12/2019
0.18 09/04/2019 08/07/2019 09/05/2019 09/14/2019
0.18 06/03/2019 05/15/2019 06/04/2019 06/13/2019
0.18 03/04/2019 02/20/2019 03/05/2019 03/14/2019
0.17 12/03/2018 10/24/2018 12/04/2018 12/13/2018
0.17 08/31/2018 08/07/2018 09/04/2018 09/13/2018
0.17 06/04/2018 05/16/2018 06/05/2018 06/14/2018
0.17 03/05/2018 02/21/2018 03/06/2018 03/15/2018
0.15 12/05/2017 10/25/2017 12/06/2017 12/15/2017
0.15 08/31/2017 08/08/2017 09/05/2017 09/21/2017
0.15 06/02/2017 05/18/2017 06/06/2017 06/15/2017
0.15 03/03/2017 02/24/2017 03/07/2017 03/16/2017
0.15 12/02/2016 10/26/2016 12/06/2016 12/15/2016
0.15 09/01/2016 08/08/2016 09/06/2016 09/15/2016
0.15 06/02/2016 05/20/2016 06/06/2016 06/16/2016
0.15 03/03/2016 02/18/2016 03/07/2016 03/17/2016
0.15 12/01/2015 10/28/2015 12/03/2015 12/17/2015
0.15 09/01/2015 08/10/2015 09/03/2015 09/17/2015
0.15 06/04/2015 05/22/2015 06/08/2015 06/18/2015
0.15 03/05/2015 02/19/2015 03/09/2015 03/19/2015
0.15 12/02/2014 10/30/2014 12/04/2014 12/18/2014
0.15 09/02/2014 08/08/2014 09/04/2014 09/18/2014
0.15 06/05/2014 05/23/2014 06/09/2014 06/19/2014
0.15 03/06/2014 02/20/2014 03/10/2014 03/20/2014
0.15 12/03/2013 10/25/2013 12/05/2013 12/19/2013
0.15 09/03/2013 08/08/2013 09/05/2013 09/19/2013
0.15 06/06/2013 05/10/2013 06/10/2013 06/20/2013
0.15 03/07/2013 03/04/2013 03/11/2013 03/21/2013
0.15 12/05/2012 10/22/2012 12/07/2012 12/20/2012
0.15 09/05/2012 08/09/2012 09/07/2012 09/20/2012
0.15 06/07/2012 05/14/2012 06/11/2012 06/21/2012
0.15 03/06/2012 02/10/2012 03/08/2012 03/22/2012
0.15 12/07/2011 10/25/2011 12/09/2011 12/22/2011
0.15 09/07/2011 08/03/2011 09/09/2011 09/22/2011
0.15 06/08/2011 05/16/2011 06/10/2011 06/23/2011
0.25 03/08/2011 02/11/2011 03/10/2011 03/24/2011
1.00 02/16/2011 02/10/2011 02/21/2011 02/28/2011
0.25 12/08/2010 10/07/2010 12/10/2010 12/23/2010
0.25 12/08/2008 10/23/2008 12/10/2008 12/23/2008
0.25 09/08/2008 08/14/2008 09/10/2008 09/23/2008
0.25 06/06/2008 05/15/2008 06/10/2008 06/20/2008
0.25 03/07/2008 02/14/2008 03/11/2008 03/25/2008
0.25 12/05/2007 10/25/2007 12/07/2007 12/21/2007
0.25 09/05/2007 08/31/2007 09/07/2007 09/24/2007
0.25 06/13/2007 05/17/2007 06/15/2007 06/25/2007
0.25 03/07/2007 02/15/2007 03/09/2007 03/26/2007
0.25 12/06/2006 10/26/2006 12/08/2006 12/26/2006
0.25 09/06/2006 08/28/2006 09/08/2006 09/22/2006
0.25 06/07/2006 05/25/2006 06/09/2006 06/26/2006
0.25 03/08/2006 02/21/2006 03/10/2006 03/27/2006
0.25 12/07/2005 10/20/2005 12/09/2005 12/27/2005
0.25 09/07/2005 08/29/2005 09/09/2005 09/23/2005
0.25 06/08/2005 05/19/2005 06/10/2005 06/23/2005
0.25 03/08/2005 02/17/2005 03/10/2005 03/25/2005
0.25 12/08/2004 10/21/2004 12/10/2004 12/29/2004
0.25 09/09/2004 08/31/2004 09/13/2004 09/28/2004
0.25 06/09/2004 05/20/2004 06/11/2004 06/28/2004
0.25 03/09/2004 02/19/2004 03/11/2004 03/26/2004